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Abstract We review areas of overlap between nucleoside
diphosphate kinase (NDPK; nm23) and two proteins mani-
festing an equivalent diversity of action, each with many
thousands of publications. The first is a constitutively active
protein kinase, CK2 (formerly casein kinase 2), that includes
NDPK amongst its hundreds of targets. The second is an
enigmatic member of the ATP-binding cassette (ABC) family
ofmembranepumps thatnormallyhydrolyse ATPtotransport
substrates. Yet our unusual family member (ABCC7) is not a
pump but, uniquely, acts as a regulated anion channel.
ABCC7 is the cystic fibrosis transmembrane conductance
regulator (CFTR), and we discuss the highly prevalent CFTR
mutation (F508del CFTR) in terms of the uncertainties
surrounding the molecular basis of cystic fibrosis that cloud
approaches to corrective therapy. Using lysates from cells
stably expressing either wild-type or F508del CFTR, incubat-
ed with the CK2 substrate GTP, we show that the phospho-
proteomeofF508delCFTR-expressingcellsbothdiffersfrom
wild-type CFTR-expressing cells and is significantly en-
hanced in intensity by ∼1.5-fold (p<0.05, paired t test with
Bonferroni correction, n=4). Phosphorylation is about 50%
attenuated with a specific CK2 inhibitor. We propose that a
newfunctionmayexistfortheCFTRregionthatiscommonly
mutated, noting that its sequence (PGTIKENIIF508GVSY-
DEYRYR) is not only highly conserved within the C sub-
family of ABC proteins but also a related sequence is found
in NDPK. We conclude that a latent path may exist between
mutation of this conserved sequence, CK2 hyperactivity and
disease pathogenesis that might also explain the heterozygote
advantage for the common F508del CFTR mutant .
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Abbreviations
ABC ATP-binding cassette
AMPK AMP-activated kinase
BHK Baby hamster kidney
CF Cystic fibrosis
CFTR Cystic fibrosis transmembrane conductance
regulator
CK2 Protein kinase CK2 formerly casein kinase 2
DMEM Dulbecco’s modified eagle’s medium
ENaC Epithelial sodium (Na) channel
FBS Foetal bovine serum
LIMBO Loss of intra-membrane organisation
NBD
(1 and 2)
Nucleotide binding domain
NDPK Nucleoside diphosphate kinase
NIMBO Normal intra-membrane organisation
PKA Cyclic AMP-activated protein kinase A
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The common autosomal recessive disease cystic fibrosis
(CF) is found mostly in populations of European descent
and remains an enigma despite over four decades of
research with over 30,000 references in the literature. Its
molecular origin is universally agreed in only one respect,
namely after mutation of both alleles in the cystic fibrosis
transmembrane conductance regulator (CFTR; ATP-binding
cassette (ABC)C7) on human chromosome seven (Chen et
al. 2010; Aleksandrov et al. 2007), the normally sterile lung
epithelium acquires unusual bacterial flora shortly after
birth and an inflammatory destructive lung disease ensues.
After CFTR was discovered in 1989 (Riordan et al. 1989),
early investigators showed that unlike other ABC proteins,
CFTR was not a pump and therefore dissected the pathways
controlling CFTR channel function proving beyond doubt
that membrane-anchored, cyclic AMP-dependent protein
kinase (PKA) opens a transmembrane pore within CFTR
for the transport of chloride and other anions across
epithelial cell membranes (Sheppard and Welsh 1999). In
the epithelial cell, the prevailing electrochemical driving
forces across the apical membrane facing the lumen (Fig. 1,
bottom of right panel) are such that the direction of anion
flow through CFTR is passive, i.e. dependent on the
prevailing activities of other channels and transporters.
Because anion flow may be into or out of the epithelial cell,
this makes the CFTR channel useful both for secretion and
Fig. 1 In bottom left panel, it is shown how membrane-bound NDPK,
when ‘auto’ charged with phosphohistidine-118 acts as a high-energy
phosphate distributor to other proteins such as to the beta subunit of G
proteins which enables basal levels of cAMP synthesis without
classical receptor-mediated activation. In bottom right panel, phos-
phoserine at S120 inhibits phosphohistidine-118, and in vitro, CK2 is
thought to be the kinase. Should CK2 be overactive, NDPK is
predicted to be dysfunctional because no phospho-His distribution can
take place. One consequence is that cAMP falls, its product AMP falls
thus relieving AMPK-mediated inhibition of CFTR. NDPK function is
reviewed in Mehta and Orchard (2009), and the mechanisms linking
NDPK with AMPK and CFTR are described in the Treharne et al.
references in the manuscript
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tive of a sufficient electrochemical driving force, anion flow
through the pore only occurs provided enough hydrolysable
ATP is sandwiched between the closely opposed faces of
the two nucleotide binding domains (NBD1 and NBD2)
that give the ABC family their leitmotif. This is why this
channel is sometimes described as being ATP-gated, but the
spatial and temporal relationship between ATP hydrolysis
and pore opening is not agreed. For example, despite there
being abundant cellular ATP in bulk cytosol, this CFTR
pore is apparently inaccessible to external or internal anions
in the quiescent epithelial cell because the channel rarely
opens without prior cell stimulation through protein kinases
such as the cAMP-regulated PKA, and indeed, at baseline,
even when CFTR spontaneously but rarely flickers into life,
it closes again promptly (Sheppard and Welsh 1999). So
what keeps the open probability of CFTR so low in a
quiescent epithelial cell? Feedback loops are one possible
solution. One agreed inhibitory factor is the substantial,
AMP-independent activity of a CFTR-binding protein
kinase (AMP-activated kinase, AMPK) that acts on the
regulatory domain in CFTR, largely through serine-768
(King et al. 2009; Kongsuphol et al. 2009a, b). It is thought
that until this basal, inhibitory AMPK-mediated drive is
overcome by a stimulus that (hyper)activates PKA (for
simplicity, this is not shown in the model in Fig. 1); CFTR
does not open fully (King et al. 2009; Kongsuphol et al.
2009a, b). These data also demonstrated that membrane-
local destruction of cAMP, which produces AMP through
membrane-bound phosphodiesterases (Fig. 1)l o c a lt o
CFTR, may also play a role in AMPK-dependent inhibition
of CFTR.
So how might the multifunctional nucleoside diphos-
phate kinase (NDPK) fit into this picture? Zollo and
colleagues in this series of papers will focus on the role
of a class of ‘DHH’ phosphodiesterases in NDPK binding
and NDPK function, but this will not be discussed further
here. The most direct evidence lies in cytosol-free epithelial
membranes from a cell line bearing CFTR, where we
reported that NDPK co-precipitates with AMPK despite
high stringency salt washes (Treharne et al. 2009a). NDPK
is present in the purified apical membrane of many airway
species, but the exact interactions and consequences for
CFTR regulation are unknown. Our work in progress
(Fig. 1) suggests that CFTR, AMPK and NDPK form a
complex at the epithelial membrane. For example, we
observe that the phosphoserine and phosphohistidine
content of NDPK changes in an AMP-dependent and
GTP-selective manner in vitro (Treharne et al. 2009a).
The interactions are under investigation, but it is interesting
to note that, at a clinical level, independent confirmation of
our proposed links between NDPK and CF has recently
been published (Charro et al. 2009).
The ancient origins of the commonest form of cystic
fibrosis, F508del CFTR
It is a curious fact that about 50% of CF patients across the
globe are homozygous for only one type of CFTR mutation
despite the existence of over 1,500 other CFTR mutations
(Bobadilla et al. 2002). This commonest (by far) CFTR
mutant deletes only three adjacent base pairs in exon 10 to
produce an in-frame point deletion of a single
phenylalanine-508 (the correct genetic name is p.phe508del
CFTR, mostly written as F508del, Phe508del or ΔF508 in
legacy nomenclature). Crystal structures of the isolated
NBD1 domain in which this deleted phenylalanine residue
resides suggest that the amino acids surrounding this F508
site are located in an accessible intracellular position on the
roof of NBD1, just under the cell membrane, but too far
removed for any direct interaction with the large hydro-
phobic NBD1 interface forming the ATP sandwich with
NBD2 (Lewis et al. 2005). Furthermore, it is observed that
the loss of F508 only induces local changes in the structure
of NBD1 in the immediate vicinity of the missing
phenylalanine. Thus, a key challenge is to explain how a
very local change in CFTR structure leads first, to a
heterozygote advantage and second to disease, a topic to
which we will return when we consider the functional
effects of 20-mer peptides corresponding to this mutated
region.
A second curious fact emerges from analysis of the
haplotype background of the chromosome bearing this
single highly prevalent F508del CFTR mutant which
suggests that this point mutation arose only once around
50,000 years ago (Morral et al. 1994). Thus, today, between
apparently unrelated Europeans, there exists a commonality
of structure of this F508-deleted chromosome which
implies that over many hundreds of generations, this very
same chromosome increased its prevalence from a vanish-
ingly rare first CF carrier baby (the eponymous Fibrogeni-
cum, born around the time one wave of early humans left
Africa) to today’s carriage by every 50th–80th European
(with a notable northwest to southeast decreasing gradient).
The remarkable conclusion arises that, as this chromosome
7 was handed down between successive generations, a
repeated survival advantage accrued to each heterozygote
‘fibrogenic’ carrier relative to non-carriers of F508del
CFTR. It is interesting to note that up to about 50 years
ago, almost all F508del CFTR homozygotes would have
died in very early childhood because there was no therapy
to correct their malabsorption of foodstuffs because the
disease destroys the pancreas in foetal life. We will return to
this concept of healthy European ‘super-survivors’ carrying
F508del CFTR in single copy when we consider how the
deleted F508 in NBD1 could create dominant control over
protein kinase CK2 (formerly casein kinase 2), even in a
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through recently understood effects of CK2 in inflammation
and host defence (Singh and Ramji 2008).
The gap in understanding between CFTR dysfunction
and cystic fibrosis disease
For decades, disputes have occurred on the molecular
origins of CF disease that arises when a mutation is present
in each cftr allele (typically, 50% are homozygous for
F508del, 40% have a rare or very rare ‘private’ familial
mutation with F508del and the remainder either have
thousands of combinations of different rare mutations or
have no detectable CFTR mutation, see below). We have
discussed the spectrum of these mutations elsewhere
(McCormick et al. 2002). Even today, there remain many
unresolved molecular issues on the path from CFTR
mutation to clinical disease. CFTR is undoubtedly an anion
channel in epithelia lining the lung, pancreas, small bowel
and sweat duct, but the exact in vivo nature of the
negatively charged species that traverse the CFTR pore
across the apical membrane is disputed (Muchekehu and
Quinton 2010; Conner et al. 2007) and may even differ
between tissues (evidence exists for chloride, bicarbonate
and anions with epithelial surface-sterilising properties used
to attack microbes). Other disagreements centre on the
‘chicken and egg’ scenario where a myriad of cellular
compensatory mechanisms may masquerade as primary
manifestations of CF disease (Chen et al. 2010). For
example, although the epithelia lining the lungs are sterile
at birth, inflammation is a rapidly age-increasing disease
characteristic that drives childhood lung destruction leading
to premature death, mostly in mid-adult life, but even today
in parts of Europe, good outcomes to middle age only occur
provided adequate resources for therapy are available
(McCormick et al. 2010). Yet it remains disputed as to
which comes first, ion channel dysfunction producing
abnormal mucus and hence inflammation and premature
death or whether excessive pre-inflammation is primed
awaiting bacterial infection that precedes the destructive
lung disease (Chen et al. 2010). We have reviewed this
controversy recently adding our own corroborative data to
the controversial views of another group that wild-type
CFTR is an inflammation suppressor (Hunter et al. 2010)
and have recently linked NDPK to inflammation (Treharne
et al. 2009c). In contrast, Paul Quinton and colleagues from
North America have persuasively argued that loss of
CFTR-transported bicarbonate, through its damaging
effects on mucus (release and quality), is the main driver
of lung damage (Quinton 2010). A further complication is
that the relative importance of the different origins of the
fluid that hydrates the apical surface of epithelia is not
agreed (the debate centres on the different roles of CFTR in
submucosal glands versus the surface epithelium itself)
makingthecorrecttargetingofpotentialtherapiesproblematic.
Another confounding issue is that a small minority of
patients have no detectable CFTR mutations and a tiny
minority of these rare ‘phenotypically CF-like’ patients
(Azad et al. 2009) have mutations in the epithelial sodium
channel (ENaC). This may be relevant to CF because
wild-type ENaC is reported to co-localise with wild-type
CFTR (Gentzsch et al. 2009), and this interaction is
thought to attenuate ENaC channel function, thus limiting
sodium absorption and thereby preventing excessive
surface drying that drags luminal water into the submuco-
sal space along with the sodium. This is very controversial
(Chen et al. 2010) as Michael Welsh and colleagues in
Iowa find that, in young animals, sodium absorption from
lung lumen to the blood is not enhanced in a pig model of
CF where CFTR is deleted (Chen et al. 2010). This recent
paper is an example of the overall mechanistic uncertainty
into the relative importance of each ion transport process
in CF pathogenesis at different ages (Joo et al. 2010;
Quinton 2010; Sheppard and Welsh 1999). Uncertainty
has not prevented development of therapies targeted to
both secretory and absorptive disease aspects, but only
clinical trial will resolve the relative importance of
hyposecretion from glands versus hyperreabsorption of
fluid by the surface epithelium. However, measuring drug-
induced benefit based on either approach is not that easy
because in CF pathogenesis, for a given patient’sC F T R
genotype, when measured clinically against the resultant
patient phenotype, CF disease severity is dramatically
variable, even between CF siblings inheriting the same
CFTR mutation (Mekus et al. 2000). Thus, even if general
agreement existed on the optimum rank order of therapies,
measuring clinical response is still a challenge more than
20 years after the discovery of CFTR.
CFTR is part of a network of proteins near
the membrane
CF pathogenesis in the common form of CF is intrinsically
complex because a given patient’s phenotypic ‘CF’ signs on
clinical examination may be ‘secondary to or consequential
of’ an attempt by the CF-affected cell bearing two defective
CFTR copies to compensate for the absence of wild-type
CFTR protein. Normally, wild-type CFTR lies within a
membrane-delimited network containing many proteins
where it acts as a regulatory hub (Wang et al. 2006)a s
befits the term regulator in its name. Here, we define the
consequences of the absence of wild-type CFTR as loss of
intra-membrane organisation (LIMBO). Should failure to
compensate for LIMBO be the correct pathogenic notion,
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‘wild-type signal input’ in CF patient cells. It is this
approach that underpins much of current strategy to repair
the CF defect by pharmacological correction of CFTR
(function/stability) or its genetic replacement. Because the
latter remains technologically problematic, probably be-
cause an airway epithelial cell has been designed by nature
to restrict penetration by foreign DNA, it is thought by
many that a drug-based approach is most likely to succeed.
As proof of principle, a new small molecule has recently
been reported to re-open the rare mutant G551D CFTR
(<5% of alleles) which theoretically cannot transport anions
because its nucleotide sandwich is defective in ATP
hydrolysis (Accurso et al. 2010). In CF, the affected sweat
gland duct produces too much sodium and chloride because
defective G551D CFTR cannot open its pore to re-absorb
chloride which consequently, together with luminal sodium,
passes on by the chloride-impermeant apical membrane of
the sweat duct onwards to the skin surface. The proof of
principle arises because this new small molecule is the first
to partially reverse the sweat duct LIMBO abnormality,
partially reducing surface sweat chloride concentrations.
That the observed LIMBO reversal is not complete suggests
that the pathway from gene to disease is not fully understood
a n di sc o n s i s t e n tw i t ht h i sd r u g ’s unexpected effects on CFTR
mutants without this G551D-induced ATP hydrolytic defect.
Further mechanistic confusion on the path between gene
defect and disease arises when the effects of another new
small molecule (Sermet-Gaudelus et al. 2010) are analysed.
This drug is claimed to restore full-length CFTR bearing stop
mutations that normally induce nonsense-mediated CFTR
decay (for example, the G542X stop mutation in CFTR and
others like it that together account for about 10% of CFTR
mutants). At the very least, this drug, which was developed
to create read-through at single stop codons such as G542X,
should reverse the above ‘gold standard’ sweat test, but it
absolutely fails to do so, thus adding further doubt to our
ability to fully understand the path from CFTR defect to
disease.
An alternative therapeutic approach posits that CF
disease manifestations are ‘secondary’ and could result
from some new, induced effect generated by the mutated
CFTR itself, i.e. the common F508del mutant of CFTR,
even as it degrades, in cellular transit, sends out a false
signal that induces (dys)function through the miscreant
signal’s ability to create a different sort of attack on the
already damaged LIMBO network hub (as explained above,
LIMBO is induced by a missing wild-type CFTR hub
signal). A secondary, induced excess sodium absorption
would be only one example, and its advocates suggest that
pharmacological inhibition of ENaC, perhaps coupled to
prevention of excessive ENaC activation by channel-
activating proteases, is approached most likely to benefit
the CF patient (Gentzsch et al. 2009). The literature is
driven by champions of each hypothesis (Chen et al. 2010;
Gentzsch et al. 2009). But it remains to be seen whether it
is the near complete proteasomal destruction of the
common F508del mutant of CFTR that generates disease
by LIMBO that deprives the CF-affected cell of its wild-
type CFTR network hub signal, or whether the process of
destroying the mutant CFTR itself causes some unknown
but secondary cellular network disruption signal that attacks
a weakened LIMBO-affected cell. In the former model, we
have a loss of signal and in the latter we have a gain of
signal.
Channels are by no means the whole therapeutic story,
even in the LIMBO scenario (Pier et al. 1997). Shortly after
birth, CF epithelial surfaces acquire a strangely mixed
population of both gram-negative and gram-positive species
of bacteria such as pseudomonal and staphylococcal species
and another major dispute in disease pathogenesis centres
on the contribution of CFTR towards the innate immune
system (Pier et al. 1997). Interestingly, NDPK is involved
in both the cellular responses to viral invasion (as is CK2,
see below), and others in this series will describe its role in
immunological synapse function through a calcium-
sensitive potassium channel which implies that the idea of
immune dysregulation may have direct relevance to CF
pathogenesis (we will consider the interface between cell
calcium through its modulator calmodulin as a target for
CK2 below). Some consider CFTR to be central to the
bacterial invasion process by acting as a glycosylated
pattern sensing molecule reporting on the external environ-
ment when epithelial cells encounter, bind and engulf
bacteria such as salmonella species in the gut for example.
This ‘non-channel’ receptor role for CFTR is further
complicated by emerging functions attributed to the form
of CFTR that is found in very low abundance in macro-
phages, lymphocytes, neutrophils and even in the brain.
Although this nascent field lies outside the scope of the
current paper, it is reasonable to consider the idea that not
only does the CF epithelium fail to network normally
through a missing wild-type CFTR but the incoming
immune cells attracted to the epithelial surface bacteria
may also be harbouring their very own dysfunctional
CFTR, doubling the potential impact of any defect. This
also is a very controversial area (Deriy et al. 2009), and it
may be that NDPK function is playing a latent role (Punj et
al. 2000; Yilmaz et al. 2008) because a decade of host–
pathogen interactive data suggest that NDPK can be
secreted by pathogenic bacteria such as CF-characteristic
species of mucoid pseudomonas, invasive salmonella,
atypical mycobacteria and others such as species that cause
cholera. This ‘non-CF’ literature suggests that NDPK may
be a key part of the process by which the host immune
system is regulated during bacterial invasion by either
Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:473–488 477eliminating, neutering, frustrating or subverting the first
wave of professional phagocytes that traverse the epithelium
to counteract the invaders (Punj et al. 2000). Here, it is very
important to note the disparate nature of the literature
because many decades of CFTR-centric research have
stressed the role of ATP and its metabolites (Boucher
2004) in the control of ion transport through G-protein
coupled purinergic (P) receptors on epithelia (Sheppard and
Welsh 1999). Thus far, from the ‘epithelial-centred and
channel-centred’ CF field, NDPK researchers focussing on
bacteria report that certain members of the purinergic P2X-
family are also functional on phagocytes and react to high
concentrations of ATP, probably released from damaged
epithelial cells, to provoke phagocyte suicide, thus killing
any already engulfed bacteria. Through secreted bacterial
NDPK, these P2X receptors are targeted by the above
pathogenic species when they subvert macrophage function
for example, either to promote extra-epithelial bacterial
survival by killing incoming macrophages (prior to bacterial
engulfment) or, paradoxically, by enhancing macrophage
survival through apoptotic inhibition should the pathogen
need to multiply intracellularly, if that is its preferred niche.
Manybelieve thataugmentingchannelfunctionina poorly
functioning mutant CFTR will make the patient better. This
idea is challenged by a recent study (Comer et al. 2009)
examining lung function in CF patients with the above
‘severe’ G551D CFTR mutant that is supposedly devoid of
any channel activity (Briel et al. 1998)i nv i t r o .A c c o r d i n gt o
dogma, these classical, albeit rare, CF patients with ‘channel-
dead’ CFTR should have very poor lung function as they
should secrete very little chloride through CFTR. Yet the
lungs of these patients, although moderately diseased to a
severity comparable to that found in severe asthma say (75%
of their predicted function is preserved), nevertheless exhibit
significantly better lung function than age- and sex-matched
F508del CFTR homozygous CF patients who only have
50% preserved function. This disparity occurs despite the
fact that the latter mutant is supposedly absent because
almost all of it is degraded in the ER and is therefore
unavailable for ion transport. Thus, we have yet another
theory-practice paradox of a dead but present G551D CFTR
channel that is normally processed to the apical membrane
creating better functioning lungs than those with a F508del
CFTR missing channel that is degraded in the ER and
probably never reaches the apical membrane. At the very
least, these patient data challenge the widely held notion that
G551D is always a ‘severe’ CF mutation. Those proposing
the alternative ‘knock-in’ network dysfunction model would
say that after G551D mutation, the sodium channel may not
be as hyperactive as found in F508del CFTR, so we might
expect better lungs. Yet others suggest that G551D CFTR
also fails to inhibit the sodium channel in model systems
(Briel et al. 1998), and the latest animal data suggest that the
very idea of augmented sodium absorption needs to be
treated with caution rather than drugs (Chen et al. 2010). On
the other hand, those who say that channels are a distraction
would say that the very presence of a channel-dead CFTR
merely confirms that bacterial pattern recognition is intact as
a glycosylated species of CFTR is present at the apical
membrane (Pier et al. 1996) and that a better lung function
compared to F508del CFTR is exactly what they would have
predicted. It should be no surprise that over the years,
various commentators have said that cystic fibrosis defies
analysis (Kunzelmann 2001), for every argument there is a
plausible counter argument.
Here, we conjecture that it is not only the under-
standing of the processes controlling CFTR, ENaC or
bacterial pattern recognition that is likely to unlock the
secrets of CF but in addition thought should be directed
at the hidden route by which the most highly prevalent
F508del CFTR induces its myriad of altered processes
‘in cell’, which number in their hundreds. We are not
referring to ‘omic’ analyses of gene-based or protein-
b a s e da r r a y st h a ta r ea l t e r e db yl o s i n gF 5 0 8i nC F T R
expressed in different model systems such as cell lines,
biopsies from patients at different disease stages or data
from animal models. Our view is that these approaches
generate large volumes of data (Collawn et al. 2010;
Ollero et al. 2006; Pollard et al. 2006) that are useful in
the LIMBO model in that they show which groups of
proteins are likely to network with one another and with
CFTR. Indeed one such approach has recently suggested
that the isoform of NDPK involved in immune dysfunc-
tion is significantly different in the serum of CF patients
(Charro et al. 2009).
We took a different approach, grounded on the accepted
selective heterozygote advantage for F508del CFTR by first
demonstrating common ground between the ability of the
apparently constitutively active protein kinase CK2 to
control both CFTR (Treharne et al. 2009d) and ENaC
(Bachhuber et al. 2008; Kongsuphol et al. 2009a) noting in
parallel the roles of CK2 in inflammation (Singh and Ramji
2008). We began by looking for evidence to support a
secondary miscreant signal hypothesis given that CK2 is
involved in apoptosis, inflammation, viral invasion and the
correct sub-membrane anchoring of ion channels as
described elsewhere (Pagano et al. 2008, 2010). Our novel
conjecture lies at the heart of the dilemma that the
heterozygote advantage driving the high prevalence of
F508del CFTR must have repeatedly accrued to each
healthy CF carrier (see above) who not only has both
wild-type and mutant CFTR in the same cell but also must
be a super-survivor of the high childhood mortality of
around 75% that has characterised European populations,
probably for thousands of years. Thus, at the very least, our
delineation of a latent pathway from F508del CFTR to CK2
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common CFTR mutant creates a heterozygote advantage
given that, pari passu, the wild-type channel works normally
moving thousands of ions per second seemingly oblivious of
thetransitofthemutantF508delCFTRasitdegradesfromthe
ER before it ever matures at the plasma membrane. Our rather
different approach also tackles head on the problem that a
F508del CFTR heterozygote, whose remaining 50% of wild-
typeCFTRchannelsworknormally,cannotaccrueanobvious
advantagefroma defectiveionchannelhypothesisbecause no
channel defect exists in heterozygote F508del CFTR carriers
as far as we are aware. Our second argument is that wild-type
CFTR is not a very abundant protein and the F508-deleted
mutant must therefore constitute a miniscule fraction of the
total proteasomal load at any one time. Hence, we could not
see how any such cell, even if it expressed two defective
CFTR copies, could be damaged by an ER stress response
unless an amplifier from F508del CFTR was present. We
reasoned that this degraded protein must be signalling
separately from the LIMBO idea as a non-channel, signal
amplifier and looked for a signalsourcewiththe widest reach,
namely the pleiotropic protein kinase CK2.
Protein kinase CK2, a regulator of many proteins
CK2 (Meggio and Pinna 2003) is itself an enigma due to its
constitutive activity that is unlike almost all other protein
kinases which either need activating, either by another
kinase, or through the binding of a regulatory small
molecule such as cyclic AMP for PKA. In this respect,
‘master kinase’ CK2 shares common ground with NDPK,
which is also constitutively active when ATP is added,
albeit with its phosphotransfer potential towards targets
uniquely realised through a conserved histidine residue,
H118 (Fig. 1). Interestingly, in vitro data suggest that CK2
may target NDPK (Biondi et al. 1996) inhibiting NDPK
function by phosphorylating S120 near the NDPK catalytic
site at H118 (right panel in Fig 1). In addition, unlike the
overwhelming majority of protein kinases, NDPK and CK2
can both use ATP or GTP as substrates whereas most
kinases such as PKA and AMPK only use ATP.
CK2 is intrinsically complex as it may exist either as free
catalytic alpha subunits or as a composite holoenzyme
made from two alpha and two beta subunits (head and
body, respectively). Indeed, the incredible versatility in
CK2 targeting so many different substrates (Meggio and
Pinna 2003) partly depends on its unusual assembly into
two back-to-back catalytic subunit heads balanced on a beta
body pair cemented into place only after subsequent beta
subunit phosphorylation to create a stable heterotetramer.
Thus, CK2 is aptly named with the potential to target two
substrates simultaneously (see “Appendix”).
Although CK2 substrates number in their hundreds
a n dp o s s i b l yt h o u s a n d s ,t h e yc a nb ec l a s s i f i e dt oa
degree, dependent on the structural form of CK2 they
recognise. Some substrates such as heat shock proteins
(such as HSP70 and HSP90, known CFTR interactors)
are readily phosphorylated equally well by the alpha
head (i.e. when no dimeric body is present) or the
tetrameric holoenzyme. These are designated as type 1
substrates. Other substrates such as the calcium sensor
calmodulin are subtly different because, when they
encounter the CK2 holoenzyme, they do not immediately
become phosphorylated. Instead, on binding, their phos-
phorylation is initially suppressed until another moiety
(binding remotely on CK2) relieves this unusual substrate
binding-induced catalytic inhibition (importantly, this
‘relief of inhibition’ phenomenon also occurs for the
CFTR peptides corresponding to the F508 region, as
described below). And yet these type 2 substrates are
readily phosphorylated by the alpha subunits alone just
like type one substrates. In contrast, type 3 substrates
such as initiation factors for protein elongation during
ribosomal synthesis are highly selective, never becoming
phosphorylated by the catalytic head alone, only recog-
nising the assembled heterodimeric CK2 structure be-
c a u s et h e yn e e dt ob i n dt oas i t eo nt h eb e t as u b u n i tt o
enable their access to one or other catalytic head. Finally,
there exists a further complexity with respect to the fully
assembled nature of the holoenzyme. The CK2 hetero-
dimer itself becomes ‘auto’ phosphorylated at the N
terminus of each beta subunit by a different CK2
molecule. This trans-phosphorylation is considered as a
useful marker of completed holoenzyme assembly and
was unexpectedly modulated when CK2 holoenzyme and
a purified domain of CFTR-NBD1 were exposed to
peptides derived from the F508del region of CFTR (PGTI-
KENIIF508GVSYDEYRYR). Because this beta subunit
‘auto’ phosphorylation changed so dramatically when we
varied the sequence of this 20-mer peptide on either side of
F508 for example, the data implied that CK2 might be
controlled by peptides derived from that mutated domain
within CFTR. This domain is conserved in the C group of
ABC proteins. Our conjecture predicted that CK2 might
control CFTR through the site of a CFTR mutation that
generates an unexplained, multi-system CF disease.
What CK2 does to CFTR channel function
The alpha catalytic CK2 subunit has a smaller pocket near
to its ATP/GTP binding site compared to most protein
kinases because pocket size is reduced by two bulky
hydrophobic amino acids. This structural difference has
permitted the synthesis of relatively specific inhibitors.
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permeable inhibitors to cells expressing CFTR. First, with a
patch clamp pipette in the ‘cell attached’ mode that does
not perforate the cell membrane thereby minimally disturb-
ing the (normal) intra-membrane organisation, David
Sheppard and colleagues (Bristol, UK) opened CFTR
pharmacologically with a cocktail of cell-permeant PKA
activating stimuli that elevate cyclic AMP (Treharne et al.
2009d). When CK2 was subsequently inhibited, this
nascently opened CFTR closed promptly within 80 s
despite an ongoing PKA stimulus that normally keeps the
channel open. This requirement for CK2 to be active to
maintain an open PKA-activated CFTR was confirmed by
Karl Kunzelmann (Regensburg, Germany) using CFTR
over-expressed in oocytes (Treharne et al. 2009d) but
complete CFTR closure post-CK2 inhibition was not seen
in these frog eggs (∼20% residual wild-type channel
activity was retained). Yet, in both cells and oocytes,
pharmacological pre-inhibition of CK2 prevented the
subsequent opening of CFTR, despite PKA activation.
Control experiments, using oocytes over-expressing a
mutant CK2 that was engineered by Lorenzo Pinna (Padua,
Italy) to be kinase active but inhibitor insensitive (by
mutating the two bulky amino acids in the pocket
mentioned above), showed that PKA-activated CFTR was
now insensitive to closure with the very same inhibitor of
CK2. This proved that CFTR’s ability to conduct ions is
largely CK2-dependent whilst confirming that the inhibitor
had no effect on PKA or other unknown CFTR activating
proteins in the normal CFTR-organised hub. Thus, the
combined data suggest that when CFTR is stimulated by
PKA, presumably within its intact membrane hub, active
CK2 is not only required to maintain CFTR in its
maximally open (PKA-driven) state but CK2 activity is
also permissive for PKA action either to open (or keep
open) CFTR.
Next, the requirement for CFTR to be nested within
its hub of membrane-organised proteins was tested. The
very same CFTR-containing patch bearing the recently
CK2 regulated CFTR was re-studied in an excised inside
out patch clamp configuration that cuts out the patched
membrane for study by exposing its cytosolic face to the
bath solution. Interestingly, this membrane fracture from
the mother cell immediately closes CFTR requiring a re-
activating cocktail of ATP and PKA to be added to the
bath solution. Under these conditions, pharmacological
CK2 inhibition that had recently shut CFTR in the intact
cell could no longer close CFTR despite higher doses of
CK2 inhibitor (Treharne et al. 2009d). This is consistent
with the idea that either the normal intra-membrane
organisation, fractured by patch excision (fracture-induced
variant of the LIMBO idea but with wild-type CFTR
present), was vital for CK2 to act on CFTR or that
fracture-induced LIMBO displaced CK2 from wild-type
CFTR.
The F508del CFTR point mutant is a temperature-
sensitive allele that is not completely degraded at room
temperature. Thus, oocytes have the advantage over
mammalian cells that when F508del CFTR is over-
expressed, it does not degrade due to the lower temperature
of the amphibian egg. Curiously, F508del CFTR only
manifests about 20% of wild-type channel activity in
response to a maximal PKA stimulus. We wondered if this
residual activity would be CK2 dependent but found that
the PKA-activated F508del CFTR was completely CK2-
inhibitor insensitive. Thus, we are left with the speculation
that the missing 80% of PKA-driven wild-type CFTR
opening that is absent in oocytes expressing the F508del
mutant is the CK2-dependent part. However, we cannot
exclude the possibility that this mutant form of CFTR has
no bound CK2 in the vicinity of its different mutant hub of
proteins as we had observed in human airway biopsies
(Treharne et al. 2009d). Next, we switched our focus to the
reciprocal actions of CFTR on CK2, i.e. we sought the
aberrant signal generator.
What the F508 region of CFTR does to CK2 activity
Prior to these studies, we had noticed that in the immediate
vicinity of the commonly mutated F508 in CFTR lay serine
511 in a potential CK2 consensus sequence just C-terminal
to F508 (PGTIKENIIF508GVS511YDEYRYR). CK2 uses
the proximity of negatively charged amino acids such as
aspartate (D) and glutamate (E) in the example shown to
locate its target serine (or threonine) residues for phosphor-
ylation. To our surprise, in separate experiments, we had
found that 20-mer peptides made from the region straddling
this pathogenic F508 residue in CFTR were able to interfere
with the ion channel activity of CFTR in a F508-dependent
manner (Treharne et al. 2009d). We sought to explain how
20-mer peptides made from CFTR could inhibit CFTR
itself given that these CFTR-derived peptides were also
able to displace apically localised IgG in airway epithelial
biopsies (Treharne et al. 2009b), consistent with a link to
the immune system. Hence, we were fully expecting the
above peptides to be phosphorylated by CK2 but, despite
an excellent predicted consensus at S511YDE, we could
never find any stoichiometric phosphate incorporation
whether F508 was present or not. Paradoxically, we
observed quite the reverse where this CFTR peptide
appeared to be a robust inhibitor of the catalytic alpha
subunit of CK2 in vitro, especially when F508 was deleted.
These unexpected findings made us consider the idea that
such CFTR peptide fragments, as might be generated when
CFTR was degraded by the proteasome for example, might
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wild-type and F508del CFTR. In turn, this could explain
how CFTR mutation disrupts so many apparently unrelated
processes ranging from ion transport to immune dysfunc-
tion. We noted that CK2 controls a diverse array of
substrates and looked for a new ‘knock-in’ CK2 signal
that was generated by the F508del mutant given that the
wild-type CFTR was controlled by such peptides and that
the literature also contains many examples of the roles of
CK2 in immunity and inflammation (Singh and Ramji
2008). We reasoned that for this peptide control to occur,
they must first bind to CK2 and demonstrated a high
affinity, F508-dependent interaction between the 20-mer
CFTR peptides and both CK2 subunits using surface
plasmon resonance (Pagano et al. 2008). Thus, both CK2
subunits could bind to CFTR peptides straddling the F508
site, but loss of F508 did not alter the affinity of binding to
a significant degree. This made us consider the functional
effects of these peptides towards CK2.
Our principal hypothesis was that degraded CFTR,
whether wild-type or F508 mutant, generates peptide
fragments that could feedback to differentially control
CK2. Should this be correct, then these 20-mer peptides
should modulate CK2 substrate phosphorylation in an
F508-dependent manner. By applying 20-mer peptides
from the F508 region of CFTR to CK2 incubated with its
classical substrates in vitro, we demonstrated that CK2
activity against different class-specific substrates can be
differentially controlled in a F508-dependent manner
(Pagano et al. 2008, 2010). We found that these two
peptides acted with significantly greater potency against
CK2 when the F508 was deleted, regulating different
classes of CK2 substrate in different directions. Thus, one
peptide could create more than one signal just by losing
F508. For example, the very same F508-deleted peptide
that potently inhibited the in vitro catalytic activity of the
isolated CK2 alpha catalytic subunit (in the absence of the
beta subunit, see above) towards class 1 and 2 substrates
(chaperones and the cell calcium binding protein, calmod-
ulin as respective examples) nevertheless stimulated CK2
holoenzyme activity by 2–5-fold towards the very same
substrates in vitro. We interpreted this bipartite peptide
effect to suggest that the activity of any free CK2 catalytic
subunit is downregulated whilst the holoenzyme is stimu-
lated, thus fine tuning the balance of CK2 control. The
potent inhibitory effect of this CFTR-derived peptide on the
free alpha subunit also involved certain key residues on
either side of the F508 site near S511, such that the
combination of F508, V510 and the double isoleucine motif
at I506/I507 were all critical determinants of efficacy,
creating a rank order of inhibitory potential towards the
alpha subunit. Interestingly, these are the very amino acids
that are thought to lie differently oriented in the NBD1
domain structure when F508 is deleted. Next, we
modelled the site of the alpha CK2 subunit–CFTR
peptide interaction by kinetic analysis and demonstrated
that CFTR peptide induced alpha CK2 inhibition was
non-competitive against classical alpha CK2 substrates
suggestive of allosteric inhibition. Yet this was complex
allosteric control involving ATP concentration as co-
substrate because we observed sharply bent slopes of the
double reciprocal plots only when the ATP co-substrate
was present at high micromolar to millimolar concen-
trations (as might be found in cell or, perhaps, locally
enhanced by NDPK for example). In sharp contrast,
when we investigated the stimulatory effect of the CFTR
peptides on the CK2 holoenzyme, we found that the very
same CFTR-derived peptides were now behaving like
certain intensely positively charged small molecules
known to relieve the inhibition normally observed on
initial contact between the holoenzyme and type 2
substrates. This unexpected finding predicted that the
small molecules normally used to relieve class 2
substrate inhibition in vitro such as polylysine would
have their potency significantly reduced by direct
competition with the CFTR peptides and indeed this
was observed as predicted (Pagano et al. 2010). Thus, we
had the unexpected conclusion that a constitutively active
kinase, CK2 that is generally regarded as not being
controlled by endogenous substrates, could nevertheless
be regulated, in vitro by a potential naturally occurring
peptide. Next, we demonstrated that when the whole
domain of NBD1 was added to holoenzyme, NBD1 itself
behaved like a type 2 substrate with inhibited phosphor-
ylation relieved by either polylysine or the above F508del
CFTR peptides.
To demonstrate that our conjecture of a single amino
acid deletion in a channel that controls class-specific
functions of a pleiotropic kinase can have meaning in a
cellular environment, we now show some examples that
take our current in vitro observations into an established
cystic fibrosis model system.
Materials
All analytical grade reagents were from Sigma-Aldrich (St.
Louis, MO, USA) and from Bio-Rad (Hercules, CA, USA).
Monoclonal antibodies against CFTR were from the CFTR
Folding Consortium (www.cftrfolding.org). Anti-CK2 beta
subunit antibody was from Epitomics (Burlingame, CA,
USA) whereas CK2 alpha subunit antiserum was raised in
rabbit against the sequence of the human protein at C
terminus (a.a. 376–391). All other antibodies were from
Sigma and Perkin Elmer (Waltham, MA, USA). [γ-
33P]GTP
(3,000 Ci/mmol) was purchased from Hartmann Analytic
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analytically pure) was provided by Produits Chimiques
ACP Chemicals (Montreal, QC, Canada).
Cell cultures
C127 breast cancer cells engineerized to express either
wild-type or F508del CFTR were grown in Dulbecco’s
modified Eagle’s medium (DMEM) plus 10% foetal bovine
serum (FBS), 2 mM L-glutamine, penicillin (100 U/ml),
streptomycin (0.1 mg/ml) and geneticin (200 μg/ml). Baby
hamster kidney (BHK) cell lines transfected with either the
empty vector or with CFTR, either wild-type or the F508
deletion mutant, in addition to glutamine and antibiotics at
the concentrations reported for C127, required methotrexate
(500 μM) to select stable transfectants in DMEM/F12
medium plus 5% FBS. All cells were grown at 37°C in a
humidified atmosphere of 95% air and 5% CO2.
Phosphorylation assays
BHK cells were cultured to reach 70–80% confluency and
then lyzed in a buffer containing 50 mM Tris, 150 mM
NaCl, 0.5% (v/v) Triton X-100, 2 mM DTT, 1 mM EDTA,
1 mM EGTA with a cocktail of anti-proteases (Roche,
Mannheim, Germany) and anti-phosphatases (Sigma). After
protein quantitation, lysates corresponding to 130 μg were
incubated with 0.1 mM GTP/[γ-
33P]GTP (1,000 cpm/
pmol), 12 mM MgCl2, 0.1 M NaCl, 1 mM DTT with
anti-protease and anti-phosphatase cocktails and in the
absence or presence of 2 μM quinalizarin, a specific ATP-
site-directed CK2 inhibitor (Cozza et al. 2009). After
20 min incubation at 37°C, the reaction was stopped with
20 mM EDTA.
Two-dimensional gel electrophoresis
All the samples were ultracentrifuged (Beckman MLA-130
rotor) at 100,000×g at 4°C for 30 min. The supernatants were
collected and precipitated with 80% ice-cold acidic acetone
(1 mM HCl) and kept overnight at −80°C. The precipitate
was spun down at 13,000×g, 4°C for 30 min, the supernatant
was removed and the pellet was air dried. The pellet was then
r e s u s p e n d e di nab u f f e rc o n t a i n i n g7Mu r e a ,2Mt h i o u r e a ,
3% (v/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-pro-
panesulfonate, 1% (v/v)a m p h o l y t e( 3 –10), 0.5% ASB-14
and 40 mM Tris. Samples were reduced with 65 mM DTT
f o r1ha n dt h e na l k y l a t e db y1h ’s treatment with 60 mM
acrylamide. Isoelectrofocusing was performed on ReadyStrip
IPG strips, 3-10NL (Bio-Rad). For the second dimension, the
strips were equilibrated in 375 mM Tris (pH 8.8), 6 M urea,
20% glycerol (v/v) and 2% sodium dodecyl sulphate (SDS; v/
v) for 30 min. The strips were then run on 11.5% Tris–glycine
gels. Radioactive spots were imaged by a Storm Phosphor-
Imager system (Molecular Dynamics) and analysed by
OptiQuant software (Perkin Elmer).
Western blotting
Thirty micrograms of proteins from cell lysates were
resolved by SDS–polyacrylamide gel electrophoresis and
transferred onto Immobilon-P membranes (Millipore,
Billerica, MA, USA). Membranes were probed with the
indicated antibody and developed by enhanced chemilu-
minescence (Amersham Biosciences). The signal was
quantitated by chemiluminescence on Kodak Image
Station 440cf (Eastman Kodak Co., New Haven, CT,
USA) and analysed by the Kodak 1D image software.
Spot intensities were compared by analysis of variance
using data from three independent sets of cell samples.
Results
In Fig. 2, we show that in lysates from BHK cells there
does not appear to be a significant change in CK2 subunit
(s) abundance when these cells are stably transfected with
either wild-type or F508del CFTR (BHK cells, gift of C.
Farinha and M. Amaral, Lisbon). Nevertheless, when an
equal protein concentration from each lysate is radio-
labelled in the presence of [γ-
33P]GTP, a phosphodonor
substrate specific for CK2, and the radiolabelled proteins
are resolved by 2D gel electrophoresis, significant differ-
ences in the phosphorylation of many proteins become
evident when the phosphoproteomes of wild-type and
F508del cells are compared (Fig. 3a, compare panels a
and b). Notably, when compared to wild-type lysates, the
relative excess phosphorylation of all spots detectable in
panel b (F508del cell lysate) is drastically reduced by the
CK2 specific inhibitor quinalizarin (compare panels b
and c), thus providing an additional argument, besides
usage of GTP as phosphate donor, to ascribe to
endogenous CK2 most of the phosphorylating activity
detected.
To quantify differences in phosphorylation, 18 radio-
labelled areas, as indicated in Fig. 3b, were circumscribed
and analysed by OptiQuant software. From four indepen-
dent experiments, these preliminary data show that the
overwhelming majority of radioactive spots were signifi-
cantly more intense in the F508del cell lysates when
compared to wild type (p<0.05, paired t test with
Bonferroni correction, n=4), whilst a small minority were
482 Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:473–488significantly less intense (typically by ∼30%, not shown).
The phosphorylation of all areas was markedly reduced,
albeit to variable extent per spot (Table 1), by the CK2
inhibitor quinalizarin, thus confirming in a quantitative
manner the major implication of dysfunctional endogenous
CK2 in the generation of most radiolabelled proteins in an
F508del CFTR context. Thus, our preliminary analysis
suggests that spots whose phosphorylation is dramatically
enhanced by F508del CFTR expression are largely sup-
pressed by quinalizarin, as might be expected for class II
CK2 targets. The excess phosphorylation of class II targets
such as calmodulin by CK2 holoenzyme has previously
been shown to be selectively enhanced by F508del CFTR
fragments in vitro (Pagano et al. 2010). Also remarkable is
the ladder of spots included in area 4, whose behaviour is
reminiscent of variably multi-phosphorylated proteins.
Once again phosphoradiolabelling in this area is enhanced
in F508del cells whilst becoming drastically inhibited by
quinalizarin. In sharp contrast, a minority of spots appear to
be significantly less enhanced in the F508del lysates and
yet are likely to be targets of CK2 as judged from the
inhibitory efficacy of quinalizarin. We are currently
improving the resolution of the 2D gels to determine
whether these spots, when better separated from their
neighbours, represent CK2 substrates belonging to class
III, whose phosphorylation is exceptionally inhibited rather
than stimulated by F508del CFTR peptides (Pagano et al.
2010). In summary, the scenario disclosed by these experi-
ments exploiting BHK cells is consistent with our earlier
notion that in vitro, CK2 holoenzyme is susceptible to a
dual control by synthetic fragments of F508del CFTR,
resulting in variable and in some cases opposite effects on
the phosphorylation of its targets (Pagano et al. 2008,
2010).
Discussion
Here, we have attempted to account for the heterozygote
advantage from the commonest (by far) CFTR mutant by
suggesting that the deletion of F508 alters the regulation
of protein kinase CK2 in more than one direction. Our
model shown in Fig. 4 suggests that altered CK2
regulation induced by F508del CFTR could occur irre-
spective of the presence of a wild-type copy of CFTR
(compare the top and bottom of the model shown in
Fig. 4). Thus, combining Figs. 1, 3 and 4, it might be
imagined that both types of spot patterns may be present in
a heterozygote F508del CFTR carrier. The higher intensity
of F508del CFTR-induced labelling could act as an
amplifier signal because CK2 has hundreds of targets
belonging to three different classes—respectively, chaper-
ones, signal transducers and regulators of growth in
corresponding classes 1, 2 and 3. In this respect, a 20-
mer peptide with the F508 deleted that was itself not a
bona fide CK2 target nevertheless either downregulated or
upregulated each of these different target classes in vitro
depending on the structural form of CK2 they encounter.
Because we find that the effect of F508del 20-mer peptide
on a given substrate in vitro is between 2- and 20-fold
Fig. 2 Protein level of CFTR and CK2 in different wild-type (wt) and
F508del (ΔF) CFTR transfected cell lines. a Western blot analysis
performed with anti-CFTR antibody on BHK and C127 cells trans-
fected with wild-type and F508del CFTR. For BHK cells, the pattern
of transfection with the empty vector (Mock) is also present. b
Western blot analysis on BHK cells transfected with wt and F508del
CFTR performed with anti-CFTR, anti-alpha CK2 (CK2α) subunit
and anti-beta CK2 (CK2β) subunit antibodies. The protein levels of
CK2 in wild-type and F508del CFTR transfected BHK cells are
comparable. Actin was used as a loading control in all panels
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found a different path to CF disease. To set our findings
into a normal intra-membrane network context for CFTR,
in Fig. 1 we have also highlighted the potential overlap
between four proteins, CFTR, CK2, NDPK and its
membrane-bound binding partner, AMPK, each of which
induces multiply deranged cellular defects when mutated
ranging from multi-system disease (CFTR and NDPK)
through cancer (all four proteins) to defects in inflamma-
tion (AMPK, CK2), viral invasion (CK2, NDPK) and the
host–pathogen interaction with bacteria involving puriner-
gic receptors (NDPK, CFTR). We note that an indepen-
dent consortium (Charro et al. 2009) recently confirmed
our ideas, first reported more than a decade ago, that
NDPK is involved in CF pathogenesis by their invoking
NDPK as a CF biomarker. Finally, we have taken our
model into the cell where we observe significant F508del-
induced differences in CK2-dependent phosphorylation.
Furthermore, our unpublished data show that when the
two-dimensional phosphoproteome equivalent to that
s h o w ni nF i g .3 is compared in another wild-type and
mutant CFTR system using C127 cells (Fig. 2), then we
Fig. 3 a GTP-dependent phosphorylation pattern differs in lysates
from BHK cells transfected with wild-type (wt) and F508del (ΔF508)
CFTR. Representative autoradiographies of three independent experi-
ments are shown. All experiments were conducted in the presence of
GTP/[γ-
33P]GTP as a phosphate donor and, where indicated, 2 μM
quinalizarin, a specific CK2 inhibitor (Cozza et al. 2009), was applied
to establish the contribution of CK2 to the phosphorylation pattern of
BHK cells. Similar results were obtained with lysates of C127 cells
transfected with wild-type and F508del CFTR (not shown). To
quantitate the radioactivity incorporated, 18 radiolabelled areas as
indicated in b were defined and analysed by OptiQuant software.
Quantitative analysis is presented in Table 1
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(unpublished data, cells were a gift of G. Cabrini, Verona,
Italy). This provides cell-independent validation of our ideas.
In conclusion, given that firstly, CK2 is thought to
phosphorylate and inhibit NDPK in vitro at or near
serine-120, adjacent to the catalytic site on NDPK at
histidine-118; secondly, that membrane-bound NDPK and
AMPK interact; thirdly, that AMPK binds and controls
CFTR and fourthly, that NDPK both contains a similar
motif to that surrounding F508 in CFTR, near to its own
catalytic site and may be a biomarker in CF serum, we
now have a model of the normal CFTR intra-membrane
organisation (NIMBO) hub (left panel in Fig. 1)t h a ti s
amenable to dissection and refinement. The predicted
effects of this model (summarised in Fig. 4)w i l lh e l pu st o
bridge the current gap in understanding in CF pathophys-
iology by no longer exclusively focussing on what kinases
do to CFTR, but in parallel asking what CFTR does to key
Fig. 4 A model for the effects
of CFTR peptides on CK2. The
proteasome does not completely
degrade proteins to amino acids
but instead produces short pep-
tides. The model suggests that
normal intra-membrane organi-
sation (NIMBO; see text) is
promoted by wild-type (wt)
CFTR peptides (products of the
upper part of figure). When
CFTR is deleted, this signal is
missing (LIMBO, see text).
When F508del (ΔF508) CFTR
is present in a heterozygote, the
upper NIMBO signal is present
but the signal shown in the
lower figure is newly ‘knocked-
in’. In F508del CFTR homozy-
gotes, the NIMBO signal does
not exist and the text describes
those substrates for CK2 that
might be mis-regulated
Area ID, Fig. 3 Phospholabelling
Averaged (fold change) F508del vs wt (n=4) Inhibition by quinalizarin (%; n=3)
1 2.22 42
2 1.25 44
3 1.66 31
4 1.49 63
5 1.51 43
6 1.22 10
7 1.67 13
8 1.61 17
9 1.44 44
10 1.84 45
11 1.33 40
12 1.53 47
13 1.10 30
14 1.42 33
15 3.92 34
16 1.27 39
17 1.73 44
18 1.16 32
Table 1 Fold change in
quantification of
33P
incorporated in the proteins
resolved by 2D electrophoresis
from lysates of BHK cells
expressing F508del (ΔF508)
CFTR incubated in the presence
of [γ-
33P]GTP when compared
to wild-type CFTR-expressing
cells (column 1)
The inhibition data refer to the
application of quinalizarin to the
F508del lysates. Data were
derived from experiments of the
type illustrated in Fig. 2. The
radioactive areas circumscribed
and numbered as indicated in
Fig. 2b were analysed by
OptiQuant software. The 18 sets
of phosphorylation data are
expressed the mean
incorporation from three
independent experiments
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(‘regulator’)o ft h i sC F T Ra c r o n y mw h i c ht od a t em a k e s
little mechanistic sense.
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Appendix
The problem of too much or too little airway surface fluid
Space limitations preclude a comprehensive discussion of
the synthesis, trafficking, post-translational modification,
residence time and destruction rates of apical membrane
proteins that act as channels in apical membranes of
epithelia. Here, we focus on the regulation of CFTR and
ENaC that act in concert in the apical membrane facing the
outside of epithelia as follows: Like the colon, the airway
epithelium is set up to suck liquid and electrolytes from the
lumen to avoid surface flooding. In reverse, in order to first
wet the outer surface of the airway epithelium, kinase-
stimulated CFTR lies amongst those anion channels that
secrete negatively charged species such as bicarbonate and
chloride out into the apical lining fluid, but can only act
(outwardly) vectorially provided ENaC’s concurrent and
inwardly directed sodium movement that drives fluid
suction is simultaneously turned off. Otherwise, the inward
(membrane-depolarising) driving forces produced by (un-
restrained) sodium ion entry into the epithelial cell will not
permit anion secretion out of the very same cell membrane
where sodium is entering. Let us assume sodium entry
towards the very low intracellular sodium concentration
environment (∼10 mM) is somehow regulated, but in that
instance, this CFTR-regulated secretory process must retain
enough dynamic flexibility to turn ENaC on again should
CFTR-driven secretion overshoot, i.e. feedback is essential
in order to re-absorb any excess secreted fluid, thereby
preventing surface flooding and consequent impairment of
airway function (or in the colon, diarrhoea). Once flooding
is threatened, this in turn now requires CFTR and other
anion channels to act quickly in reverse mode to help re-
absorb newly secreted surface anions. To control this loop
locally, we thought that a constitutively active but regulated
controller of ENaC and CFTR would be an essential first
step.
CK2 controls ENaC (Bachhuber et al. 2008). Briefly,
Karl Kunzelmann and colleagues (Regensburg, Germany)
found that CK2 trafficked to the oocyte cell membrane only
when both phosphorylation sites for CK2 on the beta and
gamma subunits of ENaC were intact that is the normal
situation when wild-type ENaC is expressed. When both
CK2 sites were mutated to non-phosphorylatable alanines
and despite there being abundant CK2 in the bulk of the
oocyte, no CK2 fluorescence of the catalytic subunit could
be found in the oocyte membrane, which contrasted with
findings after wild-type ENaC expression, where abundant
CK2 membrane fluorescence was observed. Under these
doubly CK2 target mutated conditions, ENaC channel
activity was almost nil and yet the channel itself trafficked
normally to the membrane, just like wild type, but now
without the CK2 ‘cargo’ found associated with wild-type
ENaC. This suggests that as for CFTR, CK2 appears to be
essential for channel function. Thus, we find a pleiotropic
kinase is essential for both ENaC and CFTR to function as
channels. Since ENaC and CFTR are thought to lie in close
proximity to one another, our new conjecture is that the
recognised physiological requirement to switch off ENaC
when the cell is secreting and then rapidly switch it back on
again when the cell is absorbing fluid make the different
cellular forms of CK2 (doubly catalytic, heterotetrameric or
singly catalytic CK2 alone) that target substrates differen-
tially an attractive proposition to study given that CK2 can
also use both ATP and GTP thus adding signal pleiotropy to
the model. Separately, we found that in airway cells
expressing F508del CFTR, CK2 was missing from the
apical membrane (Treharne et al. 2009d) and previously we
have speculated on the chloride and sodium sensitivity of
membrane-localised NDPK that was lost upon NDPK
purification (see references therein). We imagine a normal
apical cell membrane: one head of CK2 targeting CFTR
(NBD1 as a class 2 target, say) whilst the other targets
ENaC (different substrate class) or even NDPK, such that
one target might be on and the other off, depending on the
nature of the CK2 signal. Note also the possibility of
NDPK acting to flux-balance ATP, GTP, ADP and GDP
near the membrane through substrate channelling. We then
imagine a F508del CFTR bearing heterozygote cell where a
new knock-in differential signal might arise from a F508del
CFTR-derived peptide(s) creating an enhanced potency of
CK2 signals to chaperones, calcium signalling through
calmodulin and the protein synthetic machinery for exam-
ple, a new signal that is many fold above that generated by
the wild-type CFTR protein as it degrades (Fig. 4). But of
course, there are many other possible ‘wiring diagrams’ that
might include bi-directional effects of CFTR on AMPK for
example, and the final model will have to incorporate
486 Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:473–488NDPK as a CK2 target and AMPK as an NDPK binding
protein, together acting as complex interacting elements
within the NIMBO hub (see main text for definition). Note
that the product of cAMP destruction is AMP, the very
molecule that further controls the baseline activity of
AMPK. At the very least, Fig. 3 demonstrates for the first
time that such a scenario is at least theoretically possible in
cell. Indeed, this project now comes back full circle to the
apical airway of the CF patient. These human studies
originated in 1991 when Mehta and colleagues began to
analyse the constitutive phosphorylation patterns they found
in lysates made from apically enriched human airway
epithelial biopsies (Treharne et al. 1994). At that time,
differences in phosphorylation pattern were repeatedly
observed between CF patient biopsies and controls (Treharne
and Mehta, unpublished), but the presence of excessive
inflammation in CF patient airways made the data difficult to
interpret. In control apical membranes from uninflamed
volunteers, constitutive, ATP- and GTP-dependent
membrane-delimited phosphorylation involving NDPK, so-
dium and anion concentrations was observed. In conclusion,
we believe that our CK2 hub hypothesis now has a strong
evidence base for further study given that we have evidence
that ranges from human data to model systems lying on the
path from CFTR mutation to disease pathogenesis.
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